DEFM14A: Clearwater Analytics to Acquire Enfusion in $1.5 Billion Deal

Clearwater Analytics is set to acquire Enfusion, a provider of SaaS solutions for investment management, in a transaction valued at approximately $1.5 billion.

Summary

• Clearwater Analytics will acquire Enfusion through a merger agreement.
• The deal is valued at approximately $1.5 billion.
• Enfusion stockholders will have the option to receive a mix of cash and Clearwater stock, all Clearwater stock, or all cash, subject to proration.
• The cash component is capped at approximately 52% of the aggregate Merger Consideration, and the stock component is approximately 48%.
• The implied value per share of Enfusion Common Stock is $11.25, contingent on the Final Parent Stock Price.
• Significant stockholders, representing approximately 45% of Enfusion's voting power, have agreed to vote in favor of the merger.
• The transaction is expected to close in the second quarter of 2025.
• Enfusion will hold a special meeting of its stockholders on April 17, 2025, to vote on the merger agreement.
• Upon closing, Enfusion will become a wholly-owned subsidiary of Clearwater, and its stock will be delisted from the NYSE.

Sentiment

Score: 7

Explanation: The document is largely positive, outlining the benefits of the acquisition for both companies and their stockholders. However, it also acknowledges potential risks and uncertainties associated with the transaction.

Positives

• Enfusion stockholders receive a premium for their shares.
• The deal provides liquidity for Enfusion stockholders.
• The combined company is expected to benefit from synergies.
• Significant stockholders support the transaction, increasing the likelihood of approval.
• The TRA termination results in a significant reduction in payment obligations for Enfusion.

Negatives

• The value of the stock portion of the consideration is subject to market fluctuations.
• The deal is subject to regulatory approvals and other closing conditions.
• Enfusion will incur transaction-related costs.
• The merger agreement restricts Enfusion's ability to pursue alternative offers.
• Certain Enfusion directors and executive officers have interests in the transaction that may differ from those of stockholders.

Risks

• The market price of Clearwater Common Stock could fluctuate, affecting the value of the consideration.
• Enfusion Securityholders may not receive all consideration in the form they elect.
• The Transactions are subject to the conditions contained in the Merger Agreement and if these conditions are not satisfied or waived, the Transactions will not be completed.
• The transactions are subject to the expiration of applicable waiting periods and the receipt of approvals, consents or clearances from regulatory authorities in the United States that could have an adverse effect on Clearwater, Enfusion or following the completion of the Transactions, Clearwater or, if not obtained, could prevent completion of the Transactions.
• Enfusions directors and executive officers have interests in the Transactions that may be different from, or in addition to, your interests as a stockholder of Enfusion more generally.
• The Merger Agreement limits Enfusions ability to pursue alternatives to the Transactions and may discourage other companies from trying to acquire Enfusion.
• The Merger Agreement subjects Enfusion to restrictions on its business activities.
• The business relationships of Clearwater and Enfusion and their respective subsidiaries may be subject to disruption due to uncertainty associated with the Transactions, which could have an adverse effect on the results of operations, cash flows and financial position of Clearwater, Enfusion and, following the completion of the Transactions, Clearwater.
• Failure to complete the Transactions could negatively affect the stock price and the future business and financial results of Enfusion.
• Clearwater expects to obtain financing in connection with the Transactions and cannot guarantee that it will be able to obtain such financing on favorable terms or at all.
• The unaudited pro forma condensed combined financial information included in this Proxy Statement/Prospectus is preliminary and the actual financial condition and results of operations after the Transactions may differ materially from them.
• Completion of the Transactions may trigger change in control provisions in certain agreements to which Enfusion is a party.
• Lawsuits may be filed in the future against Enfusion, its directors, Clearwater, Acquirer, Merger Sub and/or Merger Sub II challenging the Transactions or any one of them, and an adverse ruling in any such lawsuit may prevent completing the Transactions or completing the Transactions within the expected timeframe and/or result in substantial costs to Clearwater and Enfusion.
• The market price for Clearwater Common Stock following the Effective Time may be affected by factors different from those that historically have affected or currently affect Clearwater Common Stock and Enfusion Common Stock.
• Following completion of the Transactions, the market price of Clearwater Common Stock may be volatile, and holders of Clearwater Common Stock could lose a significant portion of their investment due to drops in the market price of Clearwater Common Stock following completion of the Transactions.
• If the Transactions are completed, Clearwater may not achieve the anticipated benefits of the Transactions, including anticipated synergies.
• The combined company may not be able to retain Clearwater and Enfusions existing customers, which could have an adverse effect on the combined companys business and operations, and third parties may terminate or alter existing contracts or relationships with Clearwater or Enfusion.
• The combined company may be exposed to increased litigation, which could have an adverse effect on the combined companys business, financial position, results of operations and cash flows.
• The financial forecasts are based on various assumptions that may not be realized.
• The opinion of the Special Committees financial advisor will not reflect changes in circumstances between the date of such opinion and the completion of the Transactions.
• After the Transactions are completed, Enfusion Stockholders will have their rights as stockholders governed by Clearwaters organizational documents.
• After the completion of the Transactions, Clearwater will be more leveraged than it is currently and the financing arrangements that Clearwater will enter into may, under certain circumstances, contain restrictions and limitations that could impact its ability to operate its business.
• You should read the discussion under the section titled The TransactionsMaterial U.S. Federal Income Tax Consequences of the Corporate Mergers for a more complete discussion of the U.S. federal income tax considerations relating to the Corporate Mergers and the ownership and disposition of any Clearwater Common Stock received in the Merger.
• If the Corporate Mergers, taken together, do not qualify as a reorganization under Section 368(a) of the Code, the U.S. Holders of Enfusion Common Stock may be required to pay U.S. federal income taxes on the value of any Clearwater Common Stock received in the Merger.

Future Outlook

Clearwater and Enfusion expect the Transactions to be completed during the second quarter of 2025, subject to stockholder and regulatory approvals and other customary closing conditions.

Management Comments

• The board of directors of Enfusion unanimously recommends that stockholders of Enfusion vote (i) FOR the Merger Agreement Proposal and (ii) FOR the Adjournment Proposal.

Industry Context

The acquisition reflects a trend of consolidation in the financial technology sector, with larger players seeking to expand their product offerings and customer base through strategic acquisitions.

Comparison to Industry Standards

• The document does not provide a direct comparison of Enfusion's financial metrics to specific industry standards.
• However, the fairness opinion from Goldman Sachs suggests that the Merger Consideration was evaluated in the context of comparable companies and transactions in the electronic technology and technology services industry.

Stakeholder Impact

• Enfusion Stockholders will receive a premium for their shares and the opportunity to participate in the growth of the combined company.
• Enfusion employees will become employees of Clearwater, with assurances of comparable compensation and benefits for at least one year.
• Customers of both companies are expected to benefit from the expanded product offerings and resources of the combined entity.

Next Steps

• Enfusion will hold a special meeting of its stockholders on April 17, 2025, to vote on the merger agreement.
• The parties will seek regulatory approvals.
• Enfusion stockholders will make elections regarding the form of consideration they wish to receive.
• The transaction is expected to close in the second quarter of 2025.

Key Dates

Keywords

merger, acquisition, enfusion, clearwater analytics, stockholders, merger agreement, consideration, financial, transactions, shares